EN 中文
Home Strategic Partnerships News Contact us
TOTAL:36 NEWS
Zhaoke Ophthalmology’s NDA for Cyclosporine A (CsA) Ophthalmic Gel for the Treatment of Dry Eye Disease is Accepted for Review by the CDE
read
2022-06-09
160
First Patient Enrolled for Zhaoke Ophthalmology’s Myopia Progression Control Drug NVK002 Phase III Bridging Clinical Trial (Mini-CHAMP) in China
read
2022-05-20
152
Visus Therapeutics, Inc., and Zhaoke Ophthalmology Limited Announce Exclusive Licensing Agreement to Commercialize BRIMOCHOL™ PF and Carbachol PF in Greater China, South Korea and Select Southeast Asian Markets for the Treatment of Presbyopia
read
2022-05-11
297
Zhaoke Ophthalmology Presented the Results of the Phase III Clinical Trial (COSMO) of CsA Ophthalmic Gel at ARVO 2022 Annual Meeting
read
2022-05-05
222
Zhaoke Ophthalmology Announces 2021 Annual Results
read
2022-03-23
322
>
Guangzhou Headquarters
Tel: 020-39062888
E-mail: info@zkoph.com
Add: No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangzhou
Hong Kong Headquarters
Tel: (852)23145100
E-mail: info@zkoph.com
Add: Unit 716, 7/F, Building 12W Phase 3, Hong Kong Science Park Shatin, Hong Kong
Wechat
Guangzhou Headquarters
Tel: 020-39062888
E-mail: info@zkoph.com
Add: No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangzhou
Hong Kong Headquarters
Tel: (852)23145100
E-mail: info@zkoph.com
Add: Unit 716, 7/F, Building 12W Phase 3, Hong Kong Science Park Shatin, Hong Kong
Wechat